ライフサイエンスコーパス: surgical therapy

1 aining probiotic sachet as an adjunct to non-surgical therapy.

2 ned to assess the effect of decision aids on surgical therapy.

3 reactive, and to discover the effect of non-surgical therapy.

4 favorable outcome with combined medical and surgical therapy.

5 ovements in medical therapy, and advances in surgical therapy.

6 adjuvant chemotherapy is critical in guiding surgical therapy.

7 l advantage in early-stage lung cancer after surgical therapy.

8 cancer in 1992 to 1999 who underwent primary surgical therapy.

9 should be evaluated for possible multimodal surgical therapy.

10 s been found to be predictive of response to surgical therapy.

11 lications and death is important in planning surgical therapy.

12 in mean PD and PAL-V were obtained following surgical therapy.

13 s of patients and to reduce the morbidity of surgical therapy.

14 , increased use of chemotherapy, and salvage surgical therapy.

15 etastases in 5 patients, excluding them from surgical therapy.

16 d there was significantly less CAL gain with surgical therapy.

17 omy, being considered a technical failure of surgical therapy.

18 ses constitutional symptoms should undergo a surgical therapy.

19 when severe, lead to complications requiring surgical therapy.

20 ase, relating pathophysiology to medical and surgical therapy.

21 of the fetal lung that are amenable to fetal surgical therapy.

22 astatic disease is crucial to the success of surgical therapy.

23 rse and remained unresponsive to medical and surgical therapy.

24 rapeutic options available to them for their surgical therapy.

25 lications and death is important in planning surgical therapy.

26 ic Heller myotomy is emerging as the optimal surgical therapy.

27 have helped to establish the indications for surgical therapy.

28 prevent stroke with appropriate medical and surgical therapy.

29 eatic cancer to facilitate possible curative surgical therapy.

30 ty and 4 patients with cardiac sarcoma after surgical therapy.

31 linical scenarios compared with conventional surgical therapy.

32 ts with BCNS and may offer an alternative to surgical therapy.

33 he shifting consensus toward more aggressive surgical therapy.

34 f survival and should be the primary goal of surgical therapy.

35 ital factors were associated with receipt of surgical therapy.

36 ted comorbidities, 273 (51%) did not receive surgical therapy.

37 20 patients (47%) with early HCC received no surgical therapy.

38 c confirmation of HCC, 246 (33%) received no surgical therapy.

39 f patients with early HCC through the use of surgical therapy.

40 fit at mid-term over medical or conventional surgical therapy.

41 rk as an adjunct to periodontal regenerative surgical therapy.

42 selecting the most appropriate patients for surgical therapy.

43 ents who are reasonable candidates for these surgical therapies.

44 terms of their responsiveness to medical or surgical therapies.

45 evidence-based medicine to the evaluation of surgical therapies.

46 h the appropriate combination of medical and surgical therapies.

47 r selecting patients following CMT for local surgical therapies.

48 enefit from aggressive adjunctive medical or surgical therapies.

49 pical steroid treatments or other medical or surgical therapies.

50 of the long-term adverse consequences of our surgical therapies.

51 c investigations, and innovative medical and surgical therapies.

52 ents and obviate the need for reconstructive surgical therapies.

53 and relies on knowledge of both medical and surgical therapies.

54 e pathogenesis, medical therapies as well as surgical therapies.

55 were collected initially, 4 weeks after non-surgical therapy, 10 weeks after surgical therapy, and y

56 he 1984 patients, 1468 had BCS as an initial surgical therapy (75.4%) and 460 had initial mastectomy,

57 d a deviation from guidelines for definitive surgical therapy, adjuvant chemotherapy, and adjuvant ho

58 ovascular clinician on the current status of surgical therapies aimed at achieving reverse ventricula

59 Knowledge of both medical and surgical therapies aimed at improving ventricular effici

60 The recognition that surgical therapy alone leads to a local failure rate of

61 Subsequent to surgical therapy, alterations in bone levels at the alve

62 ng chemotherapy responded to periodontal non-surgical therapy, although with less favorable results t

63 s on the choice for surgery and knowledge of surgical therapy among women with early-stage breast can

64 lowed us to recognize the utility of certain surgical therapies and the need to further study others.

65 severity of HF was strongly associated with surgical therapy and subsequent mortality, whereas valvu

66 f which patients will fail sphincter-sparing surgical therapy and ultimately require fecal diversion.

67 ting diseases that are not amenable to other surgical therapies, and are reasonably anticipated to be

68 screening for VUR, the benefits and risks of surgical therapy, and economic factors.

69 Eleven patients had primary surgical therapy, and five required subsequent surgery.

70 All patients received combined medical and surgical therapy, and none died, but they had serious co

71 s tumor characteristics, diagnostic studies, surgical therapy, and surveillance methods were reviewed

72 patients with infective endocarditis, use of surgical therapy, and their associations with patient ou

73 diagnosis of cholangiocarcinoma, medical and surgical therapy, and timing and outcome of liver transp

74 s after non-surgical therapy, 10 weeks after surgical therapy, and yearly during SPT.

75 tested patients; 2) the effectiveness of non-surgical therapy; and 3) the relative risk of disease pr

76 Dopaminergic and surgical therapies are associated with potentially serio

77 Surgical therapies are available for the treatment of IC

78 Novel pharmacological, immunologic, and surgical therapies are leading to improved quality of li

79 Many of these surgical therapies are still in the experimental or clin

80 A variety of promising new medical and surgical therapies are under investigation, but further

81 furcation defects compared with conventional surgical therapy are presented.

82 Medical, laser, and surgical therapy are similar to treatment of primary ope

83 oved at the end of the third month after non-surgical therapy associated with antibiotics.

84 As endovascular surgical therapies became widespread, GSR vascular case

85 specific therapy for BA; however, sequential surgical therapy begins with creation of a hepatoportoen

86 o identify incident cancer cases and initial surgical therapy both singly and in combination.

87 Medical and surgical therapy both still result in a large number of

88 ation of nutritional, medical, hormonal, and surgical therapies can be effective in preventing liver

89 Surgical therapy can be accomplished at experienced cent

90 Surgical therapy can be mutilating and often has signifi

91 Surgical therapy can be quite beneficial for patients wh

92 probing depths beyond that attained with non-surgical therapy, clinicians need to consider the advant

93 -8 levels decreased until 3 months after non-surgical therapy compared with baseline in T and G allel

94 Each patient received surgical therapy consisting of regenerative therapy usin

95 The results of surgical therapy consisting of the clinical parameters o

96 g the clinical management of these tumors as surgical therapies continue to improve.

97 alysis of data from the Clinical Outcomes of Surgical Therapy (COST) multicenter randomized trial tes

98 ample 2001-2003 [before Clinical Outcomes of Surgical Therapy (COST)] and 2005-2007 (after COST) was

99 cancers that are progressing on medical and surgical therapies designed to ablate the action of andr

100 researchers continue to explore alternative surgical therapies designed to augment cardiac function.

101 ibitors, and GLP-1 receptor antagonists) and surgical therapies (eg, laparoscopic surgery).

102 r MV dysfunction with either percutaneous or surgical therapy endorse the durability of MR reduction

103 transplantation remains the gold standard of surgical therapies for advanced and end-stage heart fail

104 ve roles of pharmacological and organ-saving surgical therapies for advanced heart failure, medical u

105 ssed the proliferation of minimally invasive surgical therapies for benign prostatic hyperplasia.

106 acial skeletal defects parallel the accepted surgical therapies for bone loss elsewhere in the skelet

107 survey the current non-medical, medical, and surgical therapies for childhood motor disorders.

108 d in outcomes with heart transplantation and surgical therapies for congenital heart disease along wi

109 Surgical therapies for fecal incontinence continue to ev

110 A variety of surgical therapies for heart failure are currently under

111 algesic drugs, vasoactive drugs, and medical/surgical therapies for intracranial hypertension.

112 and hospitalization when compared with other surgical therapies for men with benign prostatic hyperpl

113 2) to guide evaluation of transcatheter and surgical therapies for MR.

114 Current surgical therapies for prolapse now include augmentation

115 eview highlights the advances in the salvage surgical therapies for recurrent disease after definitiv

116 hysicians have developed and refined various surgical therapies for the treatment of Parkinson's dise

117 deal of work remains to be done, advances in surgical therapies for the treatment of Parkinson's dise

118 The present review discusses surgical therapies for the treatment of Parkinson's dise

119 Surgical therapy for 35,179 patients with stage I rectal

120 controlled trials focusing on endoscopic or surgical therapy for achalasia were included (734 total

121 cholesterol; and new concepts in medical and surgical therapy for acute intracerebral hemorrhage.

122 remains a very promising minimally invasive surgical therapy for benign prostatic hyperplasia with i

123 Complete AXLND as part of the surgical therapy for breast cancer has come under increa

124 Surgical therapy for chronic disease is not always warra

125 Surgical therapy for colorectal carcinoma metastatic to

126 has been adopted to extend the frontiers of surgical therapy for colorectal hepatic metastases.

127 ant advances in medical, interventional, and surgical therapy for coronary and peripheral arterial di

128 Surgical therapy for coronary artery disease needs to be

129 AC lung disease requires aggressive drug and surgical therapy for cure.

130 s to evaluate the regional pancreatectomy as surgical therapy for ductal adenocarcinoma of the pancre

131 for early HCC have expanded, but the use of surgical therapy for early HCC has not been examined in

132 ce of HCC is increasing, and the options for surgical therapy for early HCC have expanded, but the us

133 and analyze factors predictive of receipt of surgical therapy for early hepatocellular carcinoma (HCC

134 F is currently the most frequently performed surgical therapy for gastroesophageal reflux disease.

135 The most widely established surgical therapy for heart failure is cardiac transplant

136 s gained worldwide acceptance as the initial surgical therapy for infants with biliary atresia.

137 of different agents as a minimally invasive surgical therapy for LUTS associated with benign prostat

138 increasingly prominent role in contemporary surgical therapy for many common diseases.

139 lain the difficulty of selecting appropriate surgical therapy for patients with OSA using currently a

140 Generally, surgical therapy for Peyronie's disease can be divided i

141 rviving for 10 years after having definitive surgical therapy for primary cutaneous melanoma.

142 ues about the relative merits of medical and surgical therapy for primary hyperparathyroidism; based

143 stimulation (DBS) has emerged as a powerful surgical therapy for the management of treatment-resista

144 Effective surgical therapy for the most life-threatening manifesta

145 f parkinsonism, and the recent resurgence of surgical therapy for the treatment of hypokinetic and hy

146 It is a safe and effective alternative to surgical therapy for these tumors of 2 to 5 cm in size.

147 We review the history of surgical therapy for tuberculosis and reports of its rol

148 Surgical therapies formerly contraindicated for the fail

149 Surgical therapy had significantly more CAL loss than no

150 ith chronic periodontitis who, following non-surgical therapy, had one or more sites with probing dep

151 s with advanced periodontitis who, after non-surgical therapy, had one or more sites with probing dep

152 Although surgical therapy has been shown to be an effective treat

153 Surgical therapy has varied from biopsy to radical maste

154 ction therapy, the oldest minimally invasive surgical therapy, has been investigated for over 100 yea

155 re superficial at diagnosis and, after local surgical therapy, have a high rate of local recurrence a

156 urpose of this review is to discuss emerging surgical therapies in heart failure, in particular, mech

157 >/= 2 years) effect of four surgical and non-surgical therapies in treating periodontal disease.

158 cluded that compared surgical therapy to non-surgical therapy in >/= 10 patients diagnosed with chron

159 Limb-sparing surgery (LSS) was the primary surgical therapy in 144 patients; 24 received amputation

160 ndmark studies will guide the application of surgical therapy in heart failure for the foreseeable fu

161 alth-sponsored Best Endovascular Versus Best Surgical Therapy in Patients With Critical Limb Ischemia

162 limited reports on the outcomes of intraoral surgical therapy in patients with HIV, such as crown len

163 Clinical improvements after mechanical non-surgical therapy in patients with insulin-dependent diab

164 pic therapy is emerging as an alternative to surgical therapy in patients with mucosal (T1a) esophage

165 led trials that compare medical therapy with surgical therapy in patients with type 2 diabetes are li

166 ination with AFS may improve the response of surgical therapy in reducing probing depth in severe chr

167 The role of pharmacologic and surgical therapy in remodeling is evolving and may have

168 apy had significantly more CAL loss than non-surgical therapy in shallow PD.

169 d to compare the outcome of surgical and non-surgical therapy in shallow, moderate, and deep PD.

170 Current surgical therapies include ablative techniques (thalamot

171 Surgical therapy included extraction of tooth #28 and an

172 Surgical therapy included internal bevel gingivectomy co

173 y includes testosterone and GnRH analogs and surgical therapy includes mammoplasty and phalloplasty.

174 herefore, these patients can have definitive surgical therapy, including axillary dissection or maste

175 is currently a trend toward more aggressive surgical therapy, including prophylactic CLND and avoida

176 Patients received non-surgical therapy, including scaling and root planing (SR

177 ive interventions to enhance the efficacy of surgical therapy, increasing numbers of elderly people w

178 l outcomes must be used in the evaluation of surgical therapy (indeed, of all therapy) for glaucoma w

179 mulation among antiepileptic drugs and other surgical therapies is still evolving.

180 Analysis of the data further suggests that surgical therapy is a more predictable method for remova

181 Surgical therapy is currently the only proven way to ach

182 Currently, surgical therapy is largely reserved for infants failing

183 n's disease, remains unknown and medical and surgical therapy is limited.

184 Surgical therapy is not cost-effective.

185 although randomized trials demonstrate that surgical therapy is somewhat more durable and effective.

186 Currently, surgical therapy is the most effective modality in terms

187 ases, a combination of immunosuppression and surgical therapies may be required.

188 Novel pharmacological and surgical therapies may have future implications in visua

189 Despite surgical therapy, mortality in such patients is high.

190 detection of nonpalpable metastases altered surgical therapy (n = 2), demonstration of pharmacodynam

191 Patients receiving surgical therapy (n = 25) had a median survival of 27.8

192 Surgical therapy of atrial fibrillation concomitant to c

193 toneal (IP) chemotherapy is a promising post-surgical therapy of ovarian cancer, but the full potenti

194 Surgical therapy of RAAs in properly selected patients p

195 Therefore, aggressive surgical therapy of regional lymph node metastases is wa

196 s clinically driven repeat interventional or surgical therapy of the index vessel at 9 month-follow-u

197 um for guidance of medical, and particularly surgical, therapy of cutaneous malignant melanoma patien

198 Surgical therapies often result in nerve and tissue dama

199 Continuous non-surgical therapy (one or more non-surgical procedures pe

200 Numerous minimally invasive surgical therapy options have arisen and subsequently fa

201 ing systemic antibiotics during initial, non-surgical therapy or in the context of periodontal surger

202 Overall outcomes for patients who underwent surgical therapy or radiation were comparable across the

203 In this study, most patients underwent surgical therapy or watchful waiting while fewer had med

204 versies in diagnosis, patient selection, and surgical therapy, our over-arching goal should be to enf

205 n concordance with guidelines for definitive surgical therapy (P < .001), postlumpectomy radiation (P

206 omplex biliary stone disease not amenable to surgical therapy, peroral endoscopic removal, or simple

207 th locoregional disease was characterized as surgical therapy, radiation therapy, chemotherapy, or an

208 nal guidelines was determined for definitive surgical therapy, radiotherapy after breast-conserving s

209 Intermittent non-surgical therapy reduced the tooth mortality rate by 48%

210 ounding within the propensity-matched group, surgical therapy remained significantly associated with

211 Nonetheless, surgical therapy remains a cornerstone of management for

212 Whereas surgical therapy remains the most advisable therapy for

213 areas, (3) patients that receive ablative or surgical therapy require endoscopic follow-up, (4) high-

214 Surgical therapy resulted in a significant reduction of

215 ing which patients underwent endovascular or surgical therapy (revascularization and/or amputation) a

216 he next several years, whether endoscopic or surgical therapies should be considered, and whether the

217 New medical and surgical therapies should be studied specifically in thi

218 sently there is no unanimity of opinion that surgical therapy should be offered to all patients, and

219 on 871 patients in the Clinical Outcomes of Surgical Therapy Study (NCT00002575), investigating lapa

220 Along with conventional surgical therapy, systemic antibiotics may provide more

221 wed for the development of novel medical and surgical therapies that may potentially alter the standa

222 e some of the problems associated with early surgical therapies, the development of new techniques an

223 Despite the striking advances in medical and surgical therapy, the morbidity, mortality, and economic

224 In the context of contemporary medical and surgical therapy, the revolutionary procedure of cardiac

225 nts with early HCC may not be candidates for surgical therapy, these data suggest that there is a sig

226 are seeing an increase in consultations for surgical therapy to help transgender and gender-nonconfo

227 e anticipated to bring a broad transition of surgical therapy to minimally invasive (minithoracotomy

228 clinical trials were included that compared surgical therapy to non-surgical therapy in >/= 10 patie

229 linical scenarios compared with conventional surgical therapy to provide clinical guidelines for the

230 hat are refractory to medical and incisional surgical therapies, transscleral diode cyclophotocoagula

231 oorly defined and the response to medical or surgical therapy unpredictable.

232 mild to moderate periodontitis received non-surgical therapy using a piezo-ceramic device (n = 30) o

233 is now in progress to evaluate survival with surgical therapy versus survival with medical therapy.

234 The rate of capturing initial surgical therapies was similar to that of identifying ca

235 Surgical therapy was associated with a very low risk of

236 Surgical therapy was completed by four periodontists (tw

237 No surgical therapy was indicated.

238 However, the stenosis worsened and surgical therapy was needed.

239 Non-surgical therapy was provided at baseline.

240 Non-surgical therapies were completed to evaluate tissue res

241 cal management, and medical, endoscopic, and surgical therapies were described in 2003, and they are

242 cal attachment level (CAL) after initial non-surgical therapy were treated with VMIS.

243 ncy, highly resistant to current medical and surgical therapies, whose tumor cells characteristically

244 lude biological neurorestorative techniques--surgical therapies with transplantation, gene therapy, a

245 Seven patients underwent surgical therapy with all CT angiographic findings confi

246 Non-surgical therapy with systemic antibiotics is effective

247 e directives as antithetical to the goals of surgical therapy, yet little is known about surgeons' ap